// App-Quantinova.ai

: Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).

Researchers

Presenter

  • Shahneen Sandhu

Principal Investigators

  • Michael S Hofman

  • Martin R. Stockler

  • Andrew James Martin

  • Izabella Pokorski

  • Jeffrey C. Goh

  • David A. Pattison

  • Nattakorn Dhiantravan

  • Craig Gedye

  • Natalie K. Rutherford

  • Anthony M. Joshua

  • Thean Hsiang Tan

  • Ian D. Kirkwood

  • Sze Ting Lee

  • Andrew James Weickhardt

  • Ramin Alipour

  • Andrew Nguyen

  • Ian D. Davis

  • Louise Emmett

Medical Centers

  • Royal Brisbane and Women's Hospital, Herston, Australia

  • Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia

  • Department of Nuclear Medicine & PET Services, Royal Brisbane & Women’s Hospital and School of Medicine, University of Queensland, Brisbane, Australia, Brisbane, Australia

  • Calvary Mater Newcastle, Newcastle, Australia

  • Monash University Eastern Health Clinical School, Box Hill, VIC, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Olivia Newton-John Cancer Research Institute and La Trobe University, Heidelberg, Australia

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • St Vincents Hospital, Sydney, Australia

  • Austin Health, Heidelberg, Australia

  • Department of Molecular Imaging and Therapy, Austin Health and University of Melbourne

  • Royal Adelaide Hospital, Adelaide, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • 18F-fluorodeoxyglucose

Drug/Treatment

  • Ipilimumab

  • Docetaxel

  • Nivolumab

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT05150236

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved